Denial
Step 1
- Documented rationale required
HRSA published the revised notice on August 3, 2026, after a court enjoined the first version in December 2025 [2]. Scope: the CMS selected drug list for 2026 and 2027, regardless of payer [1].
| Manufacturer | Selected drugs in the pilot |
|---|---|
| AbbVie | Imbruvica, Linzess, Vraylar |
| Amgen | Enbrel, Otezla, Otezla XR |
| Astellas | Xtandi |
| AstraZeneca | Farxiga |
| Bristol Myers Squibb | Eliquis, Pomalyst |
| Boehringer Ingelheim | Jardiance, Ofev, Tradjenta |
| GSK | Breo Ellipta, Trelegy Ellipta |
| Merck | Januvia, Janumet, Janumet XR |
| Pfizer | Ibrance |
| Teva | Austedo, Austedo XR |
HRSA says it designed the pilot so rebates arrive before wholesaler terms fall due [2].
HRSA limits the data a manufacturer may request and bars purchasing and encounter-level data; manufacturers must publish a quarterly ceiling price file by NDC-11 for Medicaid acquisition-cost billing and sliding fee math [1].
| Topic | Rule in the notice and on the HRSA page |
|---|---|
| 12 pharmacy fields | Date of service and date prescribed, Rx and fill number, NDC-11, quantity, prescriber and provider IDs, 340B ID, BIN, PCN, plan ID qualifier |
| 11 medical fields | Date of service, claim and line number, unit of measure, NDC-11, quantity, rendering and provider IDs, 340B ID, plan name and ID |
| Denials not allowed | Eligibility, diversion, duplicate discount concerns, or perceived lack of WAC purchases |
| Denials allowed | Only with documented rationale, such as a Maximum Fair Price refund on the same claim |
| Data use | Pilot data may not be aggregated, shared or licensed beyond the pilot |
Step 1
Step 2
Step 3
Step 4
Walk one pilot drug from the shelf to the rebate, then write down 45 days of that drug at WAC. That is the working capital question for the board.
Only active selected drugs for price applicability years 2026 and 2027 on the CMS Medicare Drug Price Negotiation Selected Drug List, regardless of payer or indication. HRSA's approved-plan table lists ten manufacturers, all starting January 1, 2027.
Within 10 calendar days of a completed data submission, paid or denied with documentation. An incomplete return restarts the clock. Covered entities have up to 45 calendar days from dispense to submit.
No. Rebates may not be denied for eligibility, diversion or Medicaid duplicate discount concerns, or for a perceived lack of WAC purchases. Those go to HRSA, audits or administrative dispute resolution.
The pilot covers listed drugs in any setting, including clinic-administered drugs, and each manufacturer may include all covered entity types or carve out exceptions in its approved plan. Read each plan on the HRSA page.
Checked October 25, 2026. Proposed rules are not final until published; confirm against the source before relying on a number.
We trace your pilot drugs from wholesaler account to rebate claim, confirm the data fields and the Medicaid acquisition-cost logic, and give the board the working-capital number.